https://medicalcountermeasures.gov

Medical Countermeasures | USA Public Health SecurityMCM facilitates communication between federal government agencies and public stakeholders to enhance the Nation's public health emergency preparednessMedical Countermeasures | USA Public Health Security TOP BARDA Stakeholder Portal search U.S. Department of Health & Human Services Administration for Strategic Preparedness and Response An official website of the United States government Here’s how you know × Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites BARDA Stakeholder Portal search search ABOUT BARDA ABOUT BARDA ABOUT BARDA FDA Approvals BARDA Responds BARDA Sustainability JUNE 30 - JULY 1, 2025 HYBRID EVENT Leadership Biographies Working @ BARDA PARTNERSHIPS AND FUNDING PARTNERSHIPS & FUNDING PARTNER WITH US BARDA Broad Agency Announcement (BAA) BARDA’s Broad Agency Announcement (BAA) sets forth the advanced research and development Areas of Interest (AOIs) and solicits proposals focusing on these areas in order to protect the United States against public health emergency threats. BARDA Easy Broad Agency Announcement (EZ-BAA) To spur innovation, BARDA has issued its business-friendly, streamlined Easy Broad Agency Announcement (EZ-BAA) to support a number of new medical countermeasures. Request TechWatch Meeting If you are interested in partnering with the federal government on medical countermeasures, submit your ideas to a platform that reaches a host of potential federal partners. Target Product Profiles (TPP) Technology Readiness Levels (TRLs) DIVISIONS AND PROGRAM Chemical Biological, Radiological & Nuclear (CBRN) Antimicrobials Antivirals/Antitoxins Burn & Blast MCMs Chemical MCMs Radiological/Nuclear MCMs Vaccines Contract Management and Acquisitions (CMA) Clinical Development (DCD) Detection, Diagnostics, and Devices Infrastructure (DDDI) Division Of Nonclinical Development (DNCD) Division of Research, Innovation & Ventures (DRIVe) Influenza & Emerging Infectious Diseases (IEID) Vaccines Development Therapeutics Pandemic Vaccines and Adjuvants Pharmaceutical Countermeasures & Infrastructure (PCI) Regulatory & Quality Affairs (RQA) Quality Affairs Regulatory Affairs Regulatory Operations Special Initiatives PRISM: Primary Response Incident Scene Management Sepsis OTHER PROGRAMS Project NextGen Radiation Emergency Medical Management (REMM) Chemical Hazard Emergency Medical Management (CHEMM) NEWSROOM NEWSROOM BARDA's hub for web announcements, stories, research, videos, publications, and events Web Announcements Publications Stories BARDA Research Events & Meetings Archive Videos ABOUT BARDA ABOUT BARDA FDA Approvals BARDA Responds Sustainability Leadership Biographies Working @ BARDA BARDA Industry Day 2025 PARTNERSHIPS AND FUNDING PARTNERSHIPS AND FUNDING BARDA Broad Agency Announcement (BAA) BARDA Easy Broad Agency Announcement (EZ-BAA) Request TechWatch Meeting Target Product Profiles (TPP) Technology Readiness Levels (TRLs) DIVISIONS AND PROGRAM DIVISIONS AND PROGRAM Chemical Biological, Radiological & Nuclear (CBRN) Antimicrobials Antivirals/Antitoxins Burn & Blast MCMs Chemical MCMs Radiological/Nuclear MCMs Vaccines Division of Research, Innovation & Ventures (DRIVe) Influenza & Emerging Infectious Diseases (IEID) Vaccines Development Therapeutics Pandemic Vaccines and Adjuvants Regulatory & Quality Affairs (RQA) Quality Affairs Regulatory Affairs Regulatory Operations Special Initiatives Quality Affairs PRISM: Primary Response Incident Scene Management Sepsis Contract Management and Acquisitions (CMA) Clinical Development (DCD) Detection, Diagnostics, and Devices Infrastructure (DDDI) OTHER PROGRAMS NextGen Radiation Emergency Medical Management (REMM) Chemical Hazard Emergency Medical Management (CHEMM) NEWSROOM NEWSROOM Web Announcements Publications Stories BARDA Research Events & Meetings Archive Videos X I WANT TO FIND FEATURED SEARCHES: BARDA Newsroom Project NextGen TechWatch BAA BARDA Industry Day Coronavirus PRISM SAVE THE DATE Hybrid Event • June 30 - July 1, 2025 LEARN MORE BARDA Enhancing the Nation's public health security and emergency preparedness by facilitating communication on innovative products and solutions between federal agencies and public stakeholders LEARN MORE Project NextGen Enhancing our preparedness for COVID-19 strains and variants Newsroom Get the latest Partner with Us Learn about BARDA's funding opportunities ACTIVE OPPORTUNITY SPOTLIGHT Repurposing and Advancing Innovations Against Rad/Nuc Threats Program The RePAIR program is the latest step in longstanding efforts to strengthen the nation’s ability to respond to health security threats and is a critical part of BARDA's multi-year strategy. Effective medical countermeasures are needed to reduce severe morbidity and mortality caused by the systemic, multi-organ pathologies of Acute Radiation Syndrome (ARS). Additionally, these medical countermeasures must be available immediately at multiple points of care, such as pharmacies and hospitals, after a radiological or nuclear incident. LEARN MORE BARDA Programs Chemical, Biological, Radiological & Nuclear(CBRN) CBRN helps innovators develop promising MCMs from preclinical development to clinical trials and manufacturing scale-up to FDA approval. CBRN Programs Antimicrobials Antivirals & Antitoxins Burn & Blast MCMs Chemical MCMs Radiological & Nuclear MCMs Vaccines Learn More Clinical Development(DCD) Providing expert knowledge and support to BARDA’s programs in advanced product development and clinical research, including supporting BARDA clinical studies via the Clinical Studies Network (CSN). Integrated centralized resource: Our focus is BARDA’s success. Learn More Contract Management and Acquisition (CMA) CMA provides flexible and innovative acquisition solutions in support of BARDA’s mission. CMA strives to enhance the U.S. government’s contracting capabilities to respond quickly to both known and emerging public health threats. Learn More Detection, Diagnostics, and Devices Infrastructure (DDDI) DDDI invests in diagnostics and devices across the spectrum of advanced research and development, stockpiling, and domestic manufacturing capacity expansion. Learn More Nonclinical Development (DNCD) DNCD provides nonclinical models, tools, and expertise to advance MCM development. DNCD provides expertise and laboratory capacity to establish and share nonclinical models, conduct appropriate nonclinical studies to support FDA approval, and evaluate potential MCM candidates prior to BARDA investment. Learn More Research, Innovation & Ventures(DRIVe) DRIVe works to accelerate the development and availability of transformative technologies and approaches to protect Americans from health security threats. DRIVe aims to de-risk the most promising technologies and capabilities. DRIVe Programs DRIVe’s R&D Programs Ecosystem Programs Learn More Influenza & Emerging Infectious Diseases(IEID) Influenza & EID invests in advanced research and development, manufacturing capacity, and procurement of MCMs to protect the nation from pandemic influenza and other emerging infectious diseases. Influenza & EID Programs Pandemic Vaccines and Adjuvants Therapeutics Vacccines Development Learn More Pharmaceutical Countermeasures and Infrastructure (PCI) PCI provides expertise to strengthen the nation’s ability to manufacture, distribute, administer, and scale production of lifesaving MCMs. Learn More Regulatory & Quality Affairs (RQA) RQA ensures that BARDA-supported MCMs are safe, effective, and in compliance with relevant and current laws, regulations, and guidelines by providing technical expertise and innovative regulatory and policy approaches. RQA Programs Regulatory Affairs Quality Affairs Regulatory Operations Learn More Special Initiatives BARDA invests in innovative projects across our portfolio, including promising technologies, platforms, and programs. We launch and support efforts designed to accelerate and foster smaller new projects. Prism Sepsis NEWSROOM WEB ANNOUNCEMENT January 17, 2025 BARDA partners with Global Systems Engineering (GSE) to update and modernize CHEMM (Chemical Hazards Emerge... WEB ANNOUNCEMENT January 16, 2025 ASPR provides $375 million to develop a drug to prevent COVID-19 STORIES January 17, 2025 BARDA  2024: Improving National Medical Countermeasure Readiness for All Americans VIDEOS January 17, 2025 BARDA  2024: Improving National Medical Countermeasure Readiness for All Americans EVENTS/MEETINGS January 13, 2025 BARDA Vaccine Innovation Forum BARDA is leveraging prize competitions to advance vaccine innovatio... VIEW NEWSROOM An official website of the U.S. Department of Health & Human Services Looking for U.S. government information and services? Visit USA.gov Helpful Links Home Contact Us About BARDA Newsroom Partner With Us Working @ Barda Resources Website Disclaimers Privacy Policy Accessibility HHS Viewers & Players HHS Plain Language FOIA Sitemap Social Media Be the first to know about BARDA news and new awards. Sign-up for our email announcements: MedicalCountermeasures.gov © 2025enen1740957311https://medicalcountermeasures.gov

Edit your site?

What are you doing?